Crossmark

FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer’s disease

Crossref DOI link: https://doi.org/10.1186/s13195-018-0436-1

Published Online: 2018-10-24

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Novak, Petr https://orcid.org/0000-0003-2472-0865
Schmidt, Reinhold

Kontsekova, Eva

Kovacech, Branislav

Smolek, Tomas

Katina, Stanislav

Fialova, Lubica

Prcina, Michal

Parrak, Vojtech

Dal-Bianco, Peter

Brunner, Martin

Staffen, Wolfgang

Rainer, Michael

Ondrus, Matej

Ropele, Stefan

Smisek, Miroslav

Sivak, Roman

Zilka, Norbert

Winblad, Bengt

Novak, Michal
Funding

Funding for this research was provided by:

AXON NEUROSCIENCE SE
License Information

Text and Data Mining valid from 2018-10-24
More Information

Article History

Received: 24 July 2018

Accepted: 26 September 2018

First Online: 24 October 2018

Competing interests

: Authors affiliated with AXON Neuroscience SE, AXON Neuroscience CRM Services SE and AXON Neuroscience R&D Services SE receive salary from the company. The investigators’ institutions have received payments on a per-patient per-visit basis. BW has received personal fees from AXON Neuroscience SE for advisory services.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.